- Home
- PBPB vs IMMP Comparison
PBPB vs IMMP Comparison
Compare PBPB & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBPB
- IMMP
- Stock Information
- Founded
- PBPB 1977
- IMMP 1987
- Country
- PBPB United States
- IMMP Australia
- Employees
- PBPB N/A
- IMMP N/A
- Industry
- PBPB Restaurants
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- PBPB Consumer Discretionary
- IMMP Health Care
- Exchange
- PBPB Nasdaq
- IMMP Nasdaq
- Market Cap
- PBPB 313.6M
- IMMP 304.0M
- IPO Year
- PBPB 2013
- IMMP N/A
- Fundamental
- Price
- PBPB $9.31
- IMMP $1.85
- Analyst Decision
- PBPB Strong Buy
- IMMP Buy
- Analyst Count
- PBPB 3
- IMMP 2
- Target Price
- PBPB $15.33
- IMMP $8.50
- AVG Volume (30 Days)
- PBPB 338.5K
- IMMP 74.2K
- Earning Date
- PBPB 03-06-2025
- IMMP 03-25-2025
- Dividend Yield
- PBPB N/A
- IMMP N/A
- EPS Growth
- PBPB 670.59
- IMMP N/A
- EPS
- PBPB 1.31
- IMMP N/A
- Revenue
- PBPB $462,598,000.00
- IMMP $3,019,249.00
- Revenue This Year
- PBPB $5.67
- IMMP N/A
- Revenue Next Year
- PBPB $3.78
- IMMP $20.28
- P/E Ratio
- PBPB $7.11
- IMMP N/A
- Revenue Growth
- PBPB N/A
- IMMP 24.11
- 52 Week Low
- PBPB $6.28
- IMMP $1.65
- 52 Week High
- PBPB $13.48
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- PBPB 32.59
- IMMP 48.75
- Support Level
- PBPB $8.96
- IMMP $1.65
- Resistance Level
- PBPB $9.64
- IMMP $1.88
- Average True Range (ATR)
- PBPB 0.61
- IMMP 0.09
- MACD
- PBPB -0.26
- IMMP 0.01
- Stochastic Oscillator
- PBPB 9.02
- IMMP 65.00
About PBPB Potbelly Corporation
Potbelly Corp owns and franchises hundreds of limited-service restaurants specializing in sandwiches and salads, shakes. The menu includes toasty sandwiches, signature salads, soups, chili, sides, desserts, and, in breakfast locations it serves breakfast sandwiches and steel-cut oatmeal. majority of its locations are company-owned and located in the United States, with Illinois and Texas housing far more locations than any other state. The company has franchise partners in a number of countries. Excluding the United States, its franchises are in the Middle East.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.